Table 2.
DUAL I Extension Continuous Glucose Monitoring Sub-Study Baseline Characteristics
| Characteristic | IDegLira (n = 131) | IDeg (n = 64) | Liraglutide (n = 65) |
|---|---|---|---|
| Male/female, % | 55/45 | 56/44 | 46/54 |
| Age, years | 54.4 (9.3) | 55.0 (8.5) | 55.0 (10.3) |
| BMI, kg/m2 | 32.5 (4.4) | 32.4 (4.5) | 32.3 (4.8) |
| Duration of diabetes, years | 7.5 (5.7) | 7.5 (4.9) | 8.1 (5.1) |
| HbA1c, % | 8.2 (0.9) | 8.2 (0.9) | 8.3 (1.0) |
| HbA1c, mmol/mola | 66 (10) | 66 (10) | 67 (11) |
| FPG, mmol/L | 9.2 (2.3) | 9.1 (2.7) | 9.2 (2.4) |
| Fasting C-peptide, nmol/L | 0.79 (0.37)b | 0.85 (0.48)c | 0.81 (0.37)d |
Values are mean (SD) unless otherwise stated.
a
Calculated, not measured.
b
n = 127.
c
n = 62.
d
n = 63.
BMI, body mass index; CGM, continuous glucose monitoring; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; IDeg, insulin degludec; IDegLira, fixed-ratio combination of insulin degludec and liraglutide; SD, standard deviation.